Latest Antivirals Stories
LONDON, April 12, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93 percent of patients with
- In patients with compensated liver cirrhosis and genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, a difficult-to-treat population, TURQUOISE-II demonstrated SVR(12) rates of 91.8 and 95.9
Scientists at The University of Texas at Austin have discovered that a protein produced by the influenza A virus helps it outwit one of our body's natural defense mechanisms.
-SVR(12) rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic
MOSCOW, April 2, 2014 /PRNewswire/ -- Hepatera Ltd.
OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin CORK, Ireland, April 2, 2014 /PRNewswire/ -- Janssen R&D Ireland
ASHEVILLE, N.C., March 28, 2014 /PRNewswire/ -- It's hard to imagine heavyweight hematologists publicly squaring off in support of an off-label blood cancer drug.
Markets Research Reports.biz added deep and professional market research reports on "Global Cloud Computing: Infrastructure, Platforms, and Services 2014 - 2019" Market Analysis and
Markets Research Reports.biz added deep and professional market research reports on "Global Cancer Vaccines Competitor Analysis And Market Research" Market Analysis and Overview.
Markets Research Reports.biz added deep and professinal market research reports on "Global Endoscopy Market Report 2014" Market Analysis and Overview. Albany,
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.